ЗНАЧЕНИЕ РЕЗУЛЬТАТОВ ИССЛЕДОВАНИЯ COMPASS ДЛЯ КЛИНИЧЕСКОЙ ПРАКТИКИ ЗАКЛЮЧЕНИЕ СОВЕТА ЭКСПЕРТОВ ОТ 22 НОЯБРЯ 2017г .

1. Eikelboom JW, Connolly SJ, Bosch J et al. COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med, 2017, 377 (14): 1319–1330.

2. Anand S, Bosch J, Eikelboom J et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Published online November 10, 2017. http://dx.doi.org/10.1016/S0140–6736(17)32409–1

3. Connolly S, Eikelboom J, Bosch J et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, Published Online November 10, 2017. http://dx.doi.org/10.1016/S0140–6736(17)32458–3

4. World Health Organization. Cardiovascular Diseases FactSheet. http://www.who.int/mediacentre/factsheets/fs317/en/.Accessed August 2017

5. Hiramoto JS, Katz R, Weisman S et al. Gender-specific risk factors for peripheral artery disease in a voluntary screening population. J Am Heart Assoc, 2014, 3 (2): e000651.

6. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 2013, 34: 2949– 3003.

7. Aboyans V. Ricco J-B., Bartelink M–L. et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal (2017) 00, 1–60.